Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.
Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction. In a randomized controlled trials of 50 patients, clinical and angiographic outcome at 6 months was significantly improved with cilostazol, depicting a significantly smaller late loss and/or loss index.
Ochiai
M
M
Department of Medicine (Cardiology), Teikyo University School of Medicine, Tokyo, Japan. mochiai@med.teikyo-u.ac.jp
Eto
K
K
Takeshita
S
S
Yokoyama
N
N
Oshima
A
A
Kondo
K
K
Sato
T
T
Isshiki
T
T
D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D000077407:Cilostazol; D017023:Coronary Angiography / Q000187:drug effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D011292:Premedication; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D005343:Fibrinolytic Agents; D013777:Tetrazoles; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin